Benzinga | Nov 4, 2021 10:03AM EDT

Regeneron Highlights Presentations At Upcoming American Society Of Hematology Dec. 11-13

New data for REGN5458 (BCMAxCD3 bispecific antibody) in patients with heavily pre-treated multiple myeloma to be highlighted in an oral presentation

First data evaluating a combination therapy approach with pozelimab (C5 antibody) and Alnylam's cemdisiran (siRNA C5 inhibitor) in healthy volunteers

Regeneron will host an investor webcast on Monday, December 13 to provide further updates across its hematology portfolio

TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, GA.

"Our hematology portfolio continues to expand with multiple trials now underway to investigate our bispecific antibodies, RNA-based therapies and gene editing, among other approaches," said L. Andres Sirulnik, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Hematology at Regeneron. "Our diverse pipeline includes investigational medicines across several blood cancers including multiple myeloma and lymphoma, in addition to blood disorders such as paroxysmal nocturnal hemoglobinuria, aplastic anemia, amyloidosis and thrombosis. We continue to make progress across our hematology portfolio with eight assets currently in the clinic."

Regeneron data at ASH include an oral presentation with updated Phase 1 results from the completed dose escalation for REGN5458, an investigational BCMAxCD3 bispecific antibody, in patients with heavily pre-treated multiple myeloma. REGN5458 has the potential to advance treatment for patients with relapsed refractory disease, and the Phase 2 portion of this trial is currently enrolling with registrational intent. In addition, Regeneron and collaborator Alnylam will share the first data from healthy volunteers for a novel investigational combination of Regeneron's C5 antibody pozelimab and Alnylam's C5-inhibiting siRNA cemdisiran. The combination is planned to be evaluated in patients with the rare blood disorder, paroxysmal nocturnal hemoglobinuria (PNH), and other complement-driven disorders.

Additional presentations will include updated Phase 2 data investigating pozelimab monotherapy in patients with PNH, as well as analyses of real-world quality of life and treatment preferences among patients with diffuse large B-cell lymphoma to inform Regeneron's therapeutic development in this tumor type.

Investor Webcast Information

Regeneron will host a conference call and simultaneous webcast to share updates on the company's hematology portfolio on Monday, December 13 at 4:30 PM ET. To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International); conference ID 2668896. A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events.cfm. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

Regeneron Presentations at ASH:

-- Oral presentation (#160): Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a Phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma (RRMM) (Jeffrey A. Zonder, M.D.: Saturday, December 11, 12:45 PM ET)

-- Other presentations:

* Poster #1128: Pozelimab, a human monoclonal antibody against complement factor C5, provided inhibition of intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (Jun-Ho Jang, M.D., Ph.D: Saturday, December 11, 5:30-7:30 PM ET)

* Poster #1998: Interim analysis of an open-label, ascending-dose, Phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of the subcutaneously administered human monoclonal antibody pozelimab in combination with single doses of the subcutaneously administered siRNA cemdisiran in healthy volunteers (Tav? van Zyl, M.D.: Sunday, December 12, 6:00-8:00 PM ET)

* Poster #4111: Real-world health-related quality of life in patients with diffuse large B-cell lymphoma: Comparisons with reference populations and by line of therapy (Qiufei Ma: Monday, December 13, 6:00-8:00 PM ET)

* Online publication: Treatment preferences among patients with diffuse large B-cell lymphoma: A survey across western Europe and the United States of America (P. Connor Johnson)

The potential uses of REGN5458, pozelimab and cemdisiran described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.